Newsletter we sent to Firebrick shareholders todayWithout...

Newsletter we sent to Firebrick shareholders today

Without repeating what was in our ASX release, here are some of the key messages of that newsletter:

• We strongly believe that Nasodine works as a common cold treatment, but it is challenging to prove it clinically and gain regulatory approval for that indication. We are not giving up on the common cold as an indication for regulatory approval, but in parallel, we are actively looking at opportunities for Nasodine beyond that indication and beyond Australia.
• Common-sense says this product should be available everywhere, especially in the wake of the COVID-19 pandemic and our data showing that it cleared the virus in 100% of subjects. On that basis alone, in a future pandemic, I can imagine every healthcare worker and the informed public would want this product available as a nasal disinfectant, especially one that is proven to be safe in multiple human trials.
• Our plans are still forming, but we are hopeful of early sales in some countries, potentially starting in 2024.

More details on these plans will be forthcoming.

PM